Population-scale catalogue of clinically actionable pharmacogenomic variation in a large Middle Eastern Levantine cohort
This study presents the largest population-scale pharmacogenomic analysis to date in Jordan, revealing significant regional genetic variations in drug-metabolizing enzymes and establishing that nearly all participants carry at least one clinically actionable genetic variant, thereby providing a critical foundation for implementing precision medicine in the Levant.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Every person carries a unique set of instructions in their DNA that influences how their body handles the medicines they take. For some, a standard dose of a drug works perfectly; for others, the same dose might be too weak to help or strong enough to cause harm. This variation is not random noise but a predictable biological reality rooted in specific genetic differences. Scientists call this field pharmacogenomics. It seeks to understand how a person's genetic makeup changes the way their body processes medications, with the ultimate goal of moving away from a "one-size-fits-all" approach to prescribing. Instead of guessing which drug or dose will work, doctors could one day look at a patient's genetic profile to determine the safest and most effective treatment from the very start. However, to make this a reality, researchers need detailed maps of genetic variation for every population around the world. Without these maps, the advice given to a patient might be based on data from a different part of the world, leading to inaccurate predictions for their specific body.
A new study has filled a significant gap in this global map by creating the first large-scale catalog of these genetic variations for people living in Jordan. The researchers analyzed the DNA of 4,322 unrelated individuals from across the country, representing a diverse cross-section of the Levant region. By examining the genetic code of this large group, the team was able to identify which variations are common in this population and how they might affect the use of common medications. The findings reveal that the genetic landscape of Jordanians is distinct from many other groups used as global references. While the population shares some similarities with Europeans and South Asians, it possesses its own unique patterns of variation that cannot be accurately predicted by looking at data from other continents. This distinction is crucial because it means that medical guidelines developed for other populations might not apply correctly to patients in the Middle East.
The study focused on specific genes known to influence how the body breaks down or responds to drugs. When the researchers compared the Jordanian group to a global reference dataset, they found striking differences in the frequency of key genetic variants. For instance, a genetic change that causes the body to process a common transplant drug very slowly was found in nearly 90 percent of the Jordanian participants, whereas it appeared in only about 62 percent of the global reference group. Conversely, a variant that affects how the body handles certain antidepressants and blood thinners was much less common in Jordan than in the global average. These differences are not minor statistical blips; they represent fundamental shifts in how a large portion of the population will react to specific medications. The researchers also found that the genetic patterns in Jordan align much more closely with other Middle Eastern populations than with broader global groups, highlighting the importance of using regional data for medical decisions.
Perhaps the most significant finding is the sheer number of people who carry genetic instructions that could change how they are treated. The analysis showed that 99.3 percent of the participants carried at least one genetic variation that doctors could use to adjust their medication. On average, each person had genetic information relevant to six different drugs. This suggests that the potential for personalized medicine is vast in this region. The study identified specific recommendations for nearly 90 percent of the participants regarding the blood thinner warfarin, a medication where getting the dose wrong can lead to serious bleeding or clotting. Similarly, the study found that a large majority of the group would likely require different starting doses for the immunosuppressant drug tacrolimus, which is critical for organ transplant patients. These are not theoretical possibilities; the genetic evidence points to concrete, actionable changes that could prevent adverse reactions and improve treatment outcomes.
The researchers also looked at how these findings compare to other populations in the Middle East, such as those in Qatar. While there are similarities, the study uncovered important differences. For example, the frequency of genetic variations affecting how the body processes certain cholesterol medications and anti-seizure drugs varied significantly between the two neighboring countries. This level of detail proves that even within a relatively small geographic region, genetic diversity exists and matters. It argues against the idea that a single genetic profile can represent the entire Middle East. Instead, it suggests that medical strategies need to be tailored to specific populations to be effective. The study also noted that while some complex genetic areas could not be fully mapped using the technology available, the data gathered so far provides a robust foundation for future medical advances.
This work represents a major step forward in bringing precision medicine to the Levant. By establishing a reliable reference for the genetic variations common in Jordan, the study provides doctors and researchers with the tools they need to make better-informed decisions. It moves the conversation from whether genetic testing is useful to exactly which tests will provide the most value for local patients. The data suggests that implementing genetic testing for certain common drugs could prevent serious side effects and ensure that patients receive the right dose from the beginning. While the study does not yet prove that changing prescriptions based on these results will improve health outcomes in a clinical setting, it provides the essential evidence needed to design those future trials. The catalog serves as a blueprint, showing that the genetic diversity of the Jordanian population is unique, widespread, and ready to be used to improve healthcare for the people who live there.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.